Newsfeeds - Spark Newswire

3 minute read

FDA
News

Takeda Pharma Reports Results Of Phase 3 Trial On Efficacy, Safety Of Recombinant von Willebrand Factor Prophylaxis

Today, 7:16 AM

− Data Include Phase 3 Results Showing that the Primary Endpoint of Spontaneous, Treated Annualized Bleeding Rates During Prophylaxis with Recombinant von Willebrand Factor in Adults with von Willebrand Disease,

TAK

1 minute read

Moderna Extends Rally With Expanded Japanese COVID-19 Vaccine Supply Deal

By Shanthi Rexaline

Today, 7:16 AM

Moderna, Inc. (NASDAQ: MRNA) shares appear to be going from strength to strength, and the premarket price action Tuesday suggests a positive open for the fifth straight session.

MRNA

1 minute read

Japan To Buy Additional 50M Doses Of Moderna COVID-19 Vaccine

By Vandana Singh

Today, 7:16 AM

Moderna Inc (NASDAQ:MRNA) has announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co…

MRNA

1 minute read

Global
News

Moderna Partners with Takeda and the Government of Japan to Supply Additional 50M Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022

By Benzinga Newsdesk

Today, 7:16 AM

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical

MRNA

3 minute read

FDA
News

Takeda Pharma Reports European Patient Survey finds Crohn’s Disease Patients Living with Perianal Fistulas Experience a More Significant Negative Impact on Their Quality of Life than Crohn’s Disease Patients without Perianal Fistulas

By Benzinga Newsdesk

Today, 7:16 AM

The European Federation of Crohn’s and Ulcerative Colitis Associations (“EFCCA”) in collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) today announced results from one of

TAK

1 minute read

Takeda Pharmaceutical’s Premacure AB Granted Orphan Designation For ‘mecasermin rinfabate’

By Benzinga Newsdesk

Today, 7:16 AM

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=824321

TAK

5 minute read

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates

By Shanthi Rexaline

Today, 7:16 AM

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.

ALBO

4 minute read

The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus

By Shanthi Rexaline

Today, 7:16 AM

Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.

AFMD

5 minute read

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs

By Shanthi Rexaline

Today, 7:16 AM

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

ABBV

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Thursday, June 17, 2021: TAK, SRPT, PSTI, NVS, GLEO, RAVN

By Michael Horton

Today, 7:16 AM

Takeda Pharmaceutical (TAK) - 438,746 Shares Sarepta Pharmaceuticals (SRPT) - 25,742 Pluristem Therapeutics (PSTI) - 2,500 Novartis (NVS) - 349,532 Galileo Acquisition (GLEO) - 679,335 Raven Industries (RAVN) -

GLEO